China Drug Safety: Will Bioequivalence Testing Help Clean Up China’s Generics Industry?
This article was originally published in PharmAsia News
Executive Summary
New SFDA requirements for bioequivalence testing could help accelerate consolidation in China’s generics industry.
You may also be interested in...
China Releases New Drug GMPs; Domestic Consolidation Expected To Accelerate
SHANGHAI - China's State FDA released its long-awaited good manufacturing practices guidelines for pharmaceutical products Feb. 12, which will begin to be implemented in all new drug manufacturing sites in March
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.